A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Фаза 3
Идёт, набор закрыт
NCT06143878
| Заболевание | Plaque Psoriasis |
|---|
| Фаза | Фаза 3 |
|---|
| Спонсор | Janssen Research & Development, LLC |
|---|
| Статус | Идёт, набор закрыт |
|---|
| Участники | 774 участн. |
|---|
| Вмешательство | JNJ-77242113, JNJ-77242113 Matching Placebo, Deucravacitinib, Deucravacitinib Matching Placebo |
|---|
| Дата начала | 1.02.2024 |
|---|
| Дата завершения | 17.09.2024 |
|---|
| Публикация результатов | 25.06.2026 |
|---|
Кратко
The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and a Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 16
Week 16 · Percentage of participants
| Arm 1: Placebo Followed by JNJ-77242113 200 mg | 10.9 Percentage of participants |
|---|
| Arm 2: JNJ-77242113 200 mg | 68.5 Percentage of participants |
|---|
| p-value | <0.001 |
|---|
| Treatment difference | 57.6 (95% CI 49.9–64.2) |
|---|
Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 at Week 16
Week 16 · Percentage of participants
| Arm 1: Placebo Followed by JNJ-77242113 200 mg | 3.8 Percentage of participants |
|---|
| Arm 2: JNJ-77242113 200 mg | 55.0 Percentage of participants |
|---|
| p-value | <0.001 |
|---|
| Treatment difference | 51.2 (95% CI 44.5–57.3) |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Другие исследования по этому заболеванию
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.